HMPV in China: Is it similar to Covid-19 virus?

TDT | agencies

Email: mail@newsofbahrain.com

China is witnessing a concerning rise in respiratory illnesses, with Human Metapneumovirus (HMPV) emerging as a significant pathogen of interest. Although no official state of emergency has been declared, the country’s health authorities have implemented protocols to address unknown pathogens since December 2024.

According to a Reuters report, the surge in respiratory infections— caused by influenza A , Mycoplasma pneumoniae, Covid-19, and now HMPV—has raised alarms. In response, China’s disease control authority recently piloted a monitoring system specifically for pneumonia of unknown origin, anticipating a seasonal spike in infections during winter and spring.

The report high light d an upward trend of HMPV cases in northern provinces, particularly among children under the age of 14. Social media posts that seem to show overcrowded hospitals in China have added to public anxiety, with claims of China declaring an emergency over HMPV. However, there has been no official confirmation of such measures.

First identified in 2001, HMPV belongs to the Pneumoviridae family, closely related to the Respiratory Syncytial Virus (RSV). The virus typically causes mild upper respiratory symptoms such as cough, runny nose, and sore throat.

However, in young children, older adults, and individuals with weakened immune systems, HMPV can lead to severe complications, including pneumonia, bronchitis, and exacerbation of chronic respiratory diseases like asthma or COPD.

The US Centers for Disease Control and Prevention (CDC) notes that HMPV infections have an incubation period of 3 to 6 days, and symptoms may progress from mild cold-like conditions to serious respiratory distress.

IS HMPV SIMILAR TO THE COVID-19 VIRUS?

While HMPV and SARS-CoV-2 (the virus responsible for Covid-19) belong to different viral families, they share striking similarities:

Respiratory Illness: Both primarily target the respiratory system, causing mild to severe infections.

Transmission: Spread occurs through respiratory droplets and contact with contaminated surfaces.

Symptoms: Fever, cough, sore throat, wheezing, and shortness of breath are common.

Vulnerable Groups: Children, the elderly, and immunocompromised individuals are at higher risk.

Prevention: Standard measures like hand hygiene, mask-wearing, and social distancing help curb transmission. However, a key difference lies in vaccination availability.

While effective vaccines exist for Covid-19, no vaccine is currently available for HMPV. Besides this, antiviral treatments are limited for HMPV, unlike Covid-19, which has treatments like Paxlovid.